NCT06705725View on ClinicalTrials.gov

Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

December 26, 2024

Primary Completion Date

October 25, 2027

Study Completion Date

February 22, 2028

Conditions
Multiple Myeloma
Interventions
DRUG

CBG002 CAR-T Cell Suspension

"Single dose of CAR+ T cells will be infused, and classic 3+3 dose escalation will be applied."

Sponsors
All Listed Sponsors
lead

Carbiogene Therapeutics Co. Ltd.

INDUSTRY